Are women losing out on pharmacy’s top jobs?

  The majority of pharmacy’s workforce are women, so why do men continue to secure the top jobs? I’m writing this on a train returning home...

NHS’s prophecy is threatened as the game changes

  This year is the 70th anniversary of the NHS; that embodiment of the Good Samaritan parable admirably rooted in the Christian socialism of 1940s...

What’s the future for healthcare data?

  We’re just getting used to it, but will healthcare data become federated in the future? An overwhelming trend in 2018 will be increasing restrictions around...

Driving innovative relationships in the evolving NHS

THE SITUATION Environmental change: Healthcare delivery’s metamorphosis Last month, in the January issue of Pf Magazine, I discussed evolving accountable care systems and organisations. The key...

Martin Moth on digital’s answer to our weight problem

Britain has a weight problem that can only be solved with honest interaction and digital functionality. Speak your weight machines – where have they gone?...

NHS commissioning landscape about to become treacherous

Commission accomplished? A landscape that once stood on the precipice of functionality has since become a treacherous maze. I have a useful ‘pivot table’ listing the...

Customer facing effectiveness: Time for a new approach?

The era of customer centricity has arrived. But what’s the best way for pharma to engage? Words by Samir Paul One of the areas we have...

What does the Life Sciences Sector Deal really mean?

  Big deal The UK has a huge amount to offer the life sciences sector. It combines globally renowned scientific research bases with a...

Cold comfort: The Christmas period can be isolating for many

    Cold comfort The festive season can be a stressful time for most of us and it’s even harder for those struggling with...

Latest articles

Maxwellia makes two new appointments

Maxwellia expand their team with two new appointments

Maxwellia has expanded their team of switch experts with two new appointments following their relocation to the Alderley Park Accelerator. 
BMS & Boston Medical Center enter collaboration

BMS & Boston Medical Center announce research collaboration

BMS & Boston Medical Center enter research collaboration to investigate markers of immuno-oncology response and resistance Bristol-Myers Squibb Company...
Syringe with liquid

EC approves KEYTRUDA® as adjuvant therapy

MSD (Merck in the U.S. and Canada) has announced that the European Commission has approved its anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment...